-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Banking on Buyouts in Biotech: Is It Smart?
Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim.
Cash in on Boomers with Senior REITs
Health Care REIT just acquired Sunrise Senior Living, making the high-yield pick an even better play on the long-term demographic of aging Baby Boomers.
Cracked Wood in Market Resistance Zone Spells Trouble
Markets may be getting ahead of themselves at this point, and savvy investors may want to revisit some portfolio names that have run up, including these pharmas
Which Sectors Should Outperform for the Rest of the Year?
September kicks off a volatile period, creating opportunities for traders and investors. Find out what sectors are the most likely to outperform the market.
3 Reasons CVS Caremark Looks Healthy
CVS reported strong earnings on Monday -- and Wall Street punished it in any case. The market’s gut reaction missed a lot of positives.
Israel: Beyond the Risk, Opportunities Beckon
When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.
Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?
Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena's numbers. They might be pleasantly surprised.
How to Pick the Best High-Yield Stocks in Big Pharma
Big Pharma is a great place to find yield, and health care is a sure-fire long-term bet. But rather than shake a stick at this sector, go ahead ... be picky.
HCA Hospitals Questioned About ‘Unnecessary’ Heart Surgeries
The nation's largest for-profit hospital chain is reportedly under scrutiny for cardiology services at about 10 of its 163 hospitals.
CVS Caremark Tops Q2 Profit, Misses on Revenue
CVS Caremark posted increased second-quarter earnings that topped Wall Street forecasts, but missed on revenue, and raised its earnings outlook for the year.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
Pfizer Tops Q2 Earnings Estimates
Pfizer posted second-quarter earnings that topped Wall Street estimates even as revenue declined compared to last year.
Should I Buy Merck? 3 Pros, 3 Cons
Pharma is a tough game, but thanks to its simultaneous continued R&D spending and cost-cutting, Merck has what it takes to win. Or does it?
3 High-Flying ETFs That Still Look Good
These three are among the best-performing funds so far this year and, comparatively speaking, look to hold their own at least in the short term.
Before You Assume the Worst for Vivus …
While there are many reasons to be pessimistic about the future of pharma stock Vivus, the research that has fueled its recent drop is not one of them.
5 Health Care Mutual Funds to Buy
As the baby boomers get creakier, health care is sure to flourish. These funds are a good way to get into this must-have sector.
Is It Time to Sell Abbott Labs?
Abbott Labs has been on a tear since October, but its technical strength is wearing thin, plus a few other factors stand to hamper this otherwise solid company.
